Every 10-Q that Bolt Biotherapeutics, Inc. (BOLT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BOLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLT filings page.
Bolt Biotherapeutics, Inc., a clinical-stage oncology company, reported a Q2 2026 net loss of $7.7 million and a six‑month net loss of $15.0 million, both narrower than in 2025 due to a major October 2025 restructuring that cut headcount by about 50% and lowered research and development and general and administrative expenses. Collaboration revenue fell sharply to $5,000 in Q2 and $31,000 for the first half, from $1.8 million and $3.0 million a year earlier, reflecting limited current collaboration activity with Toray and Genmab.
Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026. Management states this may fund operations only into the first quarter of 2027 and concludes there is substantial doubt about the company’s ability to continue as a going concern without additional capital. An $0.8 million non‑cash impairment charge was recorded on right‑of‑use assets after a sublessee gave termination notice on part of the main facility. The company continues to advance its lead ISAC candidate BDC‑4182 in an ongoing Phase 1/2 trial in gastric and gastroesophageal junction cancer.
Bolt Biotherapeutics, Inc. reported a net loss of $7.2 million for the three months ended March 31, 2026, compared with $11.0 million a year earlier, as it continues developing its Boltbody immunotherapies for cancer.
Collaboration revenue fell to $26,000 from $1.2 million, reflecting limited current activity with partners Toray and Genmab. Research and development expenses declined to $4.8 million and general and administrative expenses to $2.8 million, largely due to a 2025 restructuring that halved the workforce.
Cash, cash equivalents and marketable securities totaled $23.9 million as of March 31, 2026. Management believes this may fund operations into early 2027, but the company states there is “substantial doubt” about its ability to continue as a going concern without additional capital, and it expects to seek funding through partnerships, equity or other means.
Bolt Biotherapeutics filed its Q3 2025 10‑Q, reporting collaboration revenue of $2.169 million and a quarterly net loss of $7.144 million (basic and diluted net loss per share $3.72). Operating expenses were $9.872 million, reflecting lower R&D and G&A versus the prior year. Other income was $0.559 million, aided by interest.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $38.8 million, with total assets of $65.053 million and stockholders’ equity of $32.101 million. Management states these resources may be sufficient to fund operations into 2027, yet concluded there is substantial doubt about continuing as a going concern within one year of issuance, given dependence on collaboration income and additional financing.
The company implemented cost controls, including subleasing facilities and prior workforce reductions, and on October 1, 2025 announced a new restructuring to cut about 20 employees (~50%), with estimated charges of $1.5–$2.0 million to be recorded in Q4 2025. A 1‑for‑20 reverse stock split was effected on June 6, 2025. Shares outstanding were 1,919,441 as of November 5, 2025.